Achieve Life Sciences, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Achieve Life Sciences, Inc. (ACHV) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $168.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-05-12
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $168.00K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $56.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $112.00K.
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $167.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-03-31 | $168.00K 10-Q · filed 2026-05-12 |
| 2025-09-30 | $56.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $112.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $167.00K 10-Q · filed 2025-05-13 |
| 2024-09-30 | $56.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $112.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $167.00K 10-Q · filed 2024-05-09 |
| 2023-09-30 | $56.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $112.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $167.00K 10-Q · filed 2023-05-09 |
| 2022-09-30 | $56.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $111.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $167.00K 10-Q · filed 2022-05-12 |
| 2021-09-30 | $56.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $112.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $168.00K 10-Q · filed 2021-05-13 |
| 2020-09-30 | $56.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $111.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $167.00K 10-Q · filed 2020-05-14 |
| 2019-09-30 | $56.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $112.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $167.00K 10-Q · filed 2019-05-15 |
| 2018-09-30 | $55.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $111.00K 10-Q · filed 2018-08-08 |
| 2018-03-31 | $167.00K 10-Q · filed 2018-05-09 |
| 2017-09-30 | $56.00K 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |